Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gamma-H2AX as a Molecular Predictor of Prostate Cancer Radiosensitivity

NCT00523471 is registered in ClinicalTrials.gov with AHS Cancer Control Alberta as lead sponsor.

NCT NCT00523471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00523471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gamma-H2AX as a Molecular Predictor of Prostate Cancer Radiosensitivity
Lead sponsor
AHS Cancer Control Alberta
Phase
Observational
Overall status
Terminated
Start date
July 31, 2007
Completion date
June 30, 2010
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer